Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Rigel Pharmaceuticals (NASDAQ: RIGL) was $28.16 for the day, down -0.60% from the previous closing price of $28.33. In other words, the price has decreased by -$0.60 from its previous closing price. On the day, 0.45 million shares were traded. RIGL stock price reached its highest trading level at $28.94 during the session, while it also had its lowest trading level at $27.95.
Ratios:
Our analysis of RIGL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.66 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.68. For the most recent quarter (mrq), Quick Ratio is recorded 1.90 and its Current Ratio is at 2.02. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.47.
Piper Sandler Downgraded its Overweight to Neutral on June 08, 2022, whereas the target price for the stock was revised from $7 to $1.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Feb 04 ’25 when Schorno Dean L sold 2,036 shares for $20.92 per share. The transaction valued at 42,595 led to the insider holds 58,969 shares of the business.
Schorno Dean L sold 1,734 shares of RIGL for $38,020 on Feb 05 ’25. The EVP & Chief Financial Officer now owns 57,235 shares after completing the transaction at $21.93 per share. On Feb 04 ’25, another insider, Santos David A, who serves as the EVP, Chief Commercial Officer of the company, sold 2,125 shares for $20.92 each. As a result, the insider received 44,457 and left with 53,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RIGL now has a Market Capitalization of 513546048 and an Enterprise Value of 457780480. As of this moment, Rigel’s Price-to-Earnings (P/E) ratio for their current fiscal year is 5.20, and their Forward P/E ratio for the next fiscal year is 7.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.09. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.89 while its Price-to-Book (P/B) ratio in mrq is 6.16. Its current Enterprise Value per Revenue stands at 1.709 whereas that against EBITDA is 4.278.
Stock Price History:
The Beta on a monthly basis for RIGL is 1.20, which has changed by 0.76510906 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, RIGL has reached a high of $43.72, while it has fallen to a 52-week low of $13.57. The 50-Day Moving Average of the stock is -15.01%, while the 200-Day Moving Average is calculated to be 23.43%.
Shares Statistics:
RIGL traded an average of 609.85K shares per day over the past three months and 795500 shares per day over the past ten days. A total of 17.94M shares are outstanding, with a floating share count of 17.45M. Insiders hold about 2.70% of the company’s shares, while institutions hold 77.71% stake in the company. Shares short for RIGL as of 1757894400 were 2200707 with a Short Ratio of 3.61, compared to 1755216000 on 1985792. Therefore, it implies a Short% of Shares Outstanding of 2200707 and a Short% of Float of 12.6.
Earnings Estimates
The company has 6.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.67, with high estimates of $1.03 and low estimates of $0.16.
Analysts are recommending an EPS of between $6.02 and $0.93 for the fiscal current year, implying an average EPS of $4.91. EPS for the following year is $3.31, with 6.0 analysts recommending between $5.78 and $1.1.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $65.6M to a low estimate of $59.1M. As of. The current estimate, Rigel Pharmaceuticals’s year-ago sales were $55.31MFor the next quarter, 5 analysts are estimating revenue of $64.77M. There is a high estimate of $69.7M for the next quarter, whereas the lowest estimate is $60.9M.
A total of 5 analysts have provided revenue estimates for RIGL’s current fiscal year. The highest revenue estimate was $290.32M, while the lowest revenue estimate was $275M, resulting in an average revenue estimate of $281.09M. In the same quarter a year ago, actual revenue was $179.28MBased on 6 analysts’ estimates, the company’s revenue will be $270.23M in the next fiscal year. The high estimate is $346.4M and the low estimate is $232.65M.
